250 related articles for article (PubMed ID: 31043583)
1. 3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression.
Ni J; Hou X; Wang X; Shi Y; Xu L; Zheng X; Liu N; Qiu A; Zhuang S
Cell Death Dis; 2019 May; 10(5):355. PubMed ID: 31043583
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity.
Kim J; Long KE; Tang K; Padanilam BJ
Kidney Int; 2012 Jul; 82(2):193-203. PubMed ID: 22437413
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
4. Autophagy in proximal tubules protects against acute kidney injury.
Jiang M; Wei Q; Dong G; Komatsu M; Su Y; Dong Z
Kidney Int; 2012 Dec; 82(12):1271-83. PubMed ID: 22854643
[TBL] [Abstract][Full Text] [Related]
5. 3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.
Girard N; Bazille C; Lhuissier E; Benateau H; Llombart-Bosch A; Boumediene K; Bauge C
PLoS One; 2014; 9(5):e98176. PubMed ID: 24852755
[TBL] [Abstract][Full Text] [Related]
6. DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells.
Lee JK; Kim KC
Biochem Biophys Res Commun; 2013 Sep; 438(4):647-52. PubMed ID: 23933322
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
[TBL] [Abstract][Full Text] [Related]
8. Multi-Omics Integrated Analysis of the Protective Effect of EZH2 Inhibition in Mice with Renal Ischemia-Reperfusion Injury.
Zou S; Chen J; Zhou P; Xue M; Wu M; Wang L
Kidney Blood Press Res; 2024; 49(1):196-207. PubMed ID: 38368866
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
10. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
[TBL] [Abstract][Full Text] [Related]
11. cAMP signalling protects proximal tubular epithelial cells from cisplatin-induced apoptosis via activation of Epac.
Qin Y; Stokman G; Yan K; Ramaiahgari S; Verbeek F; de Graauw M; van de Water B; Price LS
Br J Pharmacol; 2012 Feb; 165(4b):1137-50. PubMed ID: 21745194
[TBL] [Abstract][Full Text] [Related]
12. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
[TBL] [Abstract][Full Text] [Related]
13. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
14. Proximal tubule-targeted heme oxygenase-1 in cisplatin-induced acute kidney injury.
Bolisetty S; Traylor A; Joseph R; Zarjou A; Agarwal A
Am J Physiol Renal Physiol; 2016 Mar; 310(5):F385-94. PubMed ID: 26672618
[TBL] [Abstract][Full Text] [Related]
15. The water-soluble triptolide derivative PG490-88 protects against cisplatin-induced acute kidney injury.
Kim HJ; Ravichandran K; Ozkok A; Wang Q; He Z; Jani A; Ljubanovic D; Douglas IS; Edelstein CL
J Pharmacol Exp Ther; 2014 Jun; 349(3):518-25. PubMed ID: 24727856
[TBL] [Abstract][Full Text] [Related]
16. Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro.
Zhou Y; Xu H; Xu W; Wang B; Wu H; Tao Y; Zhang B; Wang M; Mao F; Yan Y; Gao S; Gu H; Zhu W; Qian H
Stem Cell Res Ther; 2013 Apr; 4(2):34. PubMed ID: 23618405
[TBL] [Abstract][Full Text] [Related]
17. Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway.
Liu Y; Lu X; Nguyen S; Olson JL; Webb HK; Kroetz DL
Mol Pharmacol; 2013 Dec; 84(6):925-34. PubMed ID: 24092818
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone induces collagen synthesis via activation of extracellular signal-regulated kinase 1 and 2 in renal proximal tubules.
Xu G; Liu A; Liu X
Nephrology (Carlton); 2008 Dec; 13(8):694-701. PubMed ID: 19154323
[TBL] [Abstract][Full Text] [Related]
19. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.
Miranda TB; Cortez CC; Yoo CB; Liang G; Abe M; Kelly TK; Marquez VE; Jones PA
Mol Cancer Ther; 2009 Jun; 8(6):1579-88. PubMed ID: 19509260
[TBL] [Abstract][Full Text] [Related]
20. Morphological Changes Induced by TKS4 Deficiency Can Be Reversed by EZH2 Inhibition in Colorectal Carcinoma Cells.
Jacksi M; Schad E; Tantos A
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
